959 results on '"Hou, Jinlin"'
Search Results
2. A spatiotemporal atlas of mouse liver homeostasis and regeneration
3. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China
4. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma
5. CTLA4+CD4+CXCR5−FOXP3+ T cells associate with unfavorable outcome in patients with chronic HBV infection
6. Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
7. Structure-Enhanced Graph Neural ODE Network for Temporal Link Prediction
8. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
9. An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients
10. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
11. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma
12. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc–ODC1 nexus
13. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
14. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures
15. LBP-019 Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B
16. LBP-037 Role of early on-treatment serum hepatitis B virus RNA declines in the prediction of hepatocellular carcinoma risk in patients with chronic hepatitis B
17. OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
18. LBP-043 A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B
19. Alcohol induces intrahepatic humoral immunity-related suppression and delays the clearance of HBV infection
20. Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis
21. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients
22. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
23. A genetic variant of CXCR4 predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients
24. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression
25. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
26. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
27. Preparation of High Thermal Stability Amorphous SiO2-Al2O3 Composite Powder by Two-Step Calcination.
28. Tripartite Motif-Containing Protein 65 (TRIM65) Inhibits Hepatitis B Virus Transcription.
29. Serum hepatitis B virus spliced RNA proportion increases with liver disease progression in patients with chronic hepatitis B
30. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
31. Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis
32. Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg‐positive Chronic Hepatitis B Patients
33. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies
34. China Registry of Hepatitis B (CR-HepB) : Protocol and implementation of a nationwide hospital-based registry of hepatitis B
35. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
36. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis
37. Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
38. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
39. Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis.
40. Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg‐Positive Chronic Hepatitis B Patients.
41. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study
42. Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study
43. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy
44. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha
45. Prevalence of hepatitis D virus antibody positivity in Chinese patients with chronic hepatitis B virus infection
46. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma
47. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus
48. Therapeutic strategies for hepatitis B virus infection: towards a cure
49. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study
50. HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.